Gregory M. Weinhoff Sells 10,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $16.34, for a total transaction of $163,400.00. Following the transaction, the insider now owns 134,021 shares in the company, valued at approximately $2,189,903.14. This trade represents a 6.94 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Centessa Pharmaceuticals Stock Down 8.0 %

Shares of NASDAQ:CNTA opened at $14.54 on Thursday. Centessa Pharmaceuticals plc has a 1 year low of $7.75 and a 1 year high of $19.09. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The business’s 50-day moving average is $16.49 and its 200-day moving average is $16.42. The company has a market capitalization of $1.92 billion, a price-to-earnings ratio of -9.50 and a beta of 1.54.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.04. Equities research analysts predict that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Guggenheim reaffirmed a “buy” rating and set a $28.00 target price on shares of Centessa Pharmaceuticals in a research report on Wednesday. TD Cowen started coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating for the company. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $27.00 target price on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $26.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of CNTA. The Manufacturers Life Insurance Company increased its stake in Centessa Pharmaceuticals by 88.1% in the third quarter. The Manufacturers Life Insurance Company now owns 264,969 shares of the company’s stock valued at $4,237,000 after purchasing an additional 124,075 shares in the last quarter. FMR LLC raised its stake in Centessa Pharmaceuticals by 4.6% during the 3rd quarter. FMR LLC now owns 2,916,494 shares of the company’s stock worth $46,635,000 after buying an additional 129,300 shares during the period. Ally Bridge Group NY LLC acquired a new position in Centessa Pharmaceuticals during the 3rd quarter worth approximately $4,951,000. Suvretta Capital Management LLC bought a new position in Centessa Pharmaceuticals in the third quarter worth approximately $1,119,000. Finally, Walleye Capital LLC acquired a new stake in Centessa Pharmaceuticals in the third quarter valued at approximately $187,000. 82.01% of the stock is owned by institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.